NCT04168723 - TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 11, 2019

Primary Completion Date

March 5, 2020

Study Completion Date

March 5, 2020

Conditions

Healthy Volunteers

Interventions

DRUG

MD1003

Group A: Daily dose of 1200 mg of MD1003 from Day 1 to Day 8

DRUG

Moxifloxacin 400mg

Group B1: Moxifloxacin 400 mg on Day 1 Group B2: Moxifloxacin 400 mg on Day 9

DRUG

Placebo for MD1003

Group A: Placebo for MD1003 on Day -1 Group B1: Placebo for MD1003 on Day -1 Group B2: Placebo for MD1003 on Day -1

DRUG

Placebo for moxifloxacin

Group A: Placebo for moxifloxacin on Day 1 and Day 9 Group B1: Placebo for moxifloxacin on Day 9 Group B2: Placebo for moxifloxacin on Day 1

Trial Locations (1)

RECRUITING

Parexel Early Phase Clinical Unit London, London